heart
Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute
March 26, 2016 by publisher · Leave a Comment
SAN JOSE, Calif.,/NEW YORK (Reuters) – A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C. The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which
Here is the original post:
Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute